We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Gazyvaro

News List

NICE backs use of Roche's Gazyvaro with bendustamine pharmatimes
May 14, 2020
Patients with follicular lymphoma will now get NHS-funded treatment with Roche's Gazyvaro (binutuzumab)/bendamustine in England and Wales after cost regulators published guidelines backing its use in this setting.
Venclyxto gains approval in Europe pharmatimes
March 16, 2020
The European Commission has approved Venclyxto (venetoclax) in combination with Gazyvaro (obinutuzumab) for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL).
Four new medicines available via NHS Scotland pharmatimes
November 27, 2018
The Scottish Medicines Consortium has cleared funds for use of four new medicines by NHS Scotland, including Sanofi’s biologic Dupixent for dermatitis.
Roche hails 4 year NICE access deal for Gazyvaro pharmaphorum
July 27, 2017
NICE has agreed a deal with Roche on its new follicular lymphoma treatment Gazyvaro, giving the drug up to four years to prove its value to patients.